mRNA cancer vaccine shows protection at 5-year follow-up, Moderna and Merck say

In a small clinical trial, customized mRNA vaccines against high-risk skin cancers appeared to reduce the risk of cancer recurrence and death by nearly 50 percent over five years when compared with standard treatment alone. That's according to Moderna and Merck, the two pharmaceutical companies that have collaborated on the experimental cancer vaccine, called intismeran autogene (mRNA-4157 or V940).

So far, the companies have only reported the top-line results in a press release this week.